buspirone/zolmitriptan (JM-010) / Bukwang Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
buspirone/zolmitriptan (JM-010) / Bukwang Pharma
NCT02439203: Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia

Completed
2
30
RoW
JM-010, Placebo
Bukwang Pharmaceutical, Contera Pharma ApS
Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
12/15
01/16
2022-002818-16: Open-Label Extension Study of JM-010 in Parkinson’s Disease Patients With Dyskinesia

Not yet recruiting
2
60
Europe
JM-010, JM-010, Film-coated tablet
Contera Pharma A/S, Contera Pharma, Contera Pharma A/S
Parkinson's Disease Patients with Dyskinesia, Parkinson's Disease Patients with Dyskinesia, Diseases [C] - Nervous System Diseases [C10]
 
 
ASTORIA, NCT03956979 / 2017-003415-19: A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia

Completed
2
89
Europe, RoW
JM-010 group A, JM-010, JM-010 group B, Placebos, Placebo
Contera Pharma, Bukwang Pharmaceutical
Dyskinesias
03/24
03/24
SHINE, NCT04377945: Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

Terminated
2
41
US
Part 1, JM-010 component Group A, Part 1, JM-010 component Group B, Part 1, JM-010 component Group C, Part 1, Placebo Group, Part 2, JM-010 combination Group A, Part 2, JM-010 combination Group B, Part 2, JM-010 component Group C, Part 2, Placebo Group
Bukwang Pharmaceutical
Dyskinesias, Parkinson Disease
02/24
02/24
NCT05516875: Open-Label Extension Study of ASTORIA

Not yet recruiting
2
80
NA
JM-010
Contera Pharma A/S
Dyskinesias
09/24
10/24

Download Options